thought leadership

Gene therapy solution: The value of a CDMO as your end-to-end partner

With ongoing advances in science and technology, the cell and gene therapy pipeline has grown especially robust over the past few years. At present, Clinical Trials.gov shows more than 4,500 active gene therapy trials globally. In the United States, McKinsey experts expect to see 10 to 20 cell and gene therapy approvals per year over the next five years. 

This article discusses the important factors to consider when selecting an outsourcing partner for your advanced therapies. 

Download Article

 

Arrival of the Groninger INTEGRA

With the expansion of our viral drug product manufacturing facility in Rockville, Maryland well underway, we have begun...

READ MORE

Genetic Vaccine Platforms Demonstrate Their Potential

In a recent Pharmaceutical Technology article, Emergent experts provide their insights on selection of technologies for vaccine...

READ MORE

Learn more about our site in Switzerland

Located in Thörishaus, Switzerland, just outside of Bern, our European-based site has expertise in mammalian, microbial, and...

READ MORE